Results 131 to 140 of about 371,093 (352)

Circular RNA circNrip1 Interacts with SYNCRIP to Promote Neuropathic Pain by Stabilizing Tlr2 mRNA in Primary Sensory Neurons

open access: yesAdvanced Science, EarlyView.
Model of circNrip1 (cNrip1) upregulation driving neuropathic pain mechanisms. After peripheral nerve injury, increased FUS triggers the formation and upregulation of cNrip1 in injured DRG neurons. Upregulated cNrip1 recruits SYNCRIP to the 3′‐UTR of Tlr2 mRNA by binding to both, thereby promoting SYNCRIP‐triggered Tlr2 mRNA stability and increasing ...
Xiaozhou Feng   +14 more
wiley   +1 more source

Caveolin-1 Deficiency Dampens Toll-Like Receptor 4 Signaling through eNOS Activation [PDF]

open access: bronze, 2010
Muhammad K. Mirza   +7 more
openalex   +1 more source

Androgen Receptor‐Induced Lactoferrin Accelerates Prostate Tumorigenesis Through Modulating Ferroptosis

open access: yesAdvanced Science, EarlyView.
This study demonstrates that transcription factor androgen receptor (AR) directly binds the LF promoter, driving lactoferrin overexpression to promote ferritin (FTH1/FTL) upregulation and inhibit p53‐ALOX12‐mediated ferroptosis in prostate cancer. Lactoferrin could be a new potential therapeutic target in prostate cancer.
Can Liu   +18 more
wiley   +1 more source

Prognostic and clinicopathological significance of TLR4 expression in patients with breast cancer: a meta-analysis

open access: yesFrontiers in Oncology
BackgroundThe prognostic value of Toll-like receptor 4 (TLR4) in breast cancer remains to be determined. Therefore, this paper aims to conduct a meta-analysis to assess the correlation between TLR4 and clinicopathological indicators as well as survival ...
Jinxu Wen   +5 more
doaj   +1 more source

TLR‐2 and TLR‐4 expression in monocytes of newborns with late‐onset sepsis

open access: yesJornal de Pediatria (Versão em Português), 2014
Objective: To analyze toll‐like receptor (TLR)‐2 and TLR‐4 expression in monocytes of newborns with late‐onset sepsis. Methods: This prospective study included 27 full‐term newborns aged 8 to 29 days, with clinical and laboratory diagnosis of late‐onset ...
Ana C.C. Redondo   +6 more
doaj   +1 more source

Leveraging Macrophage Metabolic Reprogramming for Enhanced Anti‐Tumor Immunity

open access: yesAdvanced Science, EarlyView.
Tumor‐associated macrophages (TAMs) are key regulators of the tumor microenvironment (TME), with their metabolic states playing a critical role in tumor progression or regression. This review summarizes current understanding of TAM metabolic plasticity alongside cutting‐edge bioengineering innovations, outlining a roadmap for transforming the ...
Zhiyun Liu   +8 more
wiley   +1 more source

Oil‐Coated Nanoplastics Induce Rapid Membrane Disruption and Severe Intestinal Injury

open access: yesAdvanced Science, EarlyView.
Oil‐rich food contact dramatically amplifies MNP release from plastic takeout containers, producing oil‐coated nanoplastics with altered surface properties and rapid membrane‐disruptive effects. These particles cause severe intestinal barrier damage and immune dysfunction in mice, and risk modeling suggests that long‐term gastrointestinal burdens may ...
Ruwen Xie   +17 more
wiley   +1 more source

Hepatocyte BDNF Acts as a Novel Immune Checkpoint to Restrain TLR4‐Mediated Acute Hepatitis

open access: yesAdvanced Science, EarlyView.
This study identifies hepatocyte‐derived BDNF as an endogenous TLR4 antagonist that alleviates acute hepatitis. BDNF is downregulated in hepatocytes via REST‐mediated transcriptional repression during ALI/ALF. Mechanistically, BDNF binds to TLR4 on macrophages to suppress inflammation.
Weiwei Zhu   +15 more
wiley   +1 more source

The role of TLR-4 in chemoresistance of cancer

open access: yesDiscover Oncology
Chemotherapy, which aims to eradicate tumor cells and enhance patient survival, is a prevalent approach for tumor treatment. Nevertheless, recurrence and drug resistance resulting from consecutive chemotherapy regimens have emerged as significant factors
Yuhua Li   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy